Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41


Predicting CD4 T-cell epitopes based on antigen cleavage, MHCII presentation, and TCR recognition.

Schneidman-Duhovny D, Khuri N, Dong GQ, Winter MB, Shifrut E, Friedman N, Craik CS, Pratt KP, Paz P, Aswad F, Sali A.

PLoS One. 2018 Nov 6;13(11):e0206654. doi: 10.1371/journal.pone.0206654. eCollection 2018.


A unique major histocompatibility complex Class II-binding register correlates with HLA-DR11-associated immunogenicity of the major K blood group antigen.

Gunasekera D, Zimring JC, Pratt KP.

Transfusion. 2018 May;58(5):1171-1181. doi: 10.1111/trf.14525. Epub 2018 Feb 20.


FVIII proteins with a modified immunodominant T-cell epitope exhibit reduced immunogenicity and normal FVIII activity.

Ettinger RA, Liberman JA, Gunasekera D, Puranik K, James EA, Thompson AR, Pratt KP.

Blood Adv. 2018 Feb 27;2(4):309-322. doi: 10.1182/bloodadvances.2017013482.


Accurate, simple, and inexpensive assays to diagnose F8 gene inversion mutations in hemophilia A patients and carriers.

Dutta D, Gunasekera D, Ragni MV, Pratt KP.

Blood Adv. 2016 Dec 14;1(3):231-239. doi: 10.1182/bloodadvances.2016001651. eCollection 2016 Dec 27.


Marginal immunogenicity of factor VIII.

Pratt KP.

Blood. 2017 Dec 7;130(23):2450-2451. doi: 10.1182/blood-2017-10-811109. No abstract available.


Hemophilia A inhibitor treatment: the promise of engineered T-cell therapy.

Parvathaneni K, Abdeladhim M, Pratt KP, Scott DW.

Transl Res. 2017 Sep;187:44-52. doi: 10.1016/j.trsl.2017.06.002. Epub 2017 Jun 9. Review.


Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.

Pipe SW, Montgomery RR, Pratt KP, Lenting PJ, Lillicrap D.

Blood. 2016 Oct 20;128(16):2007-2016. doi: 10.1182/blood-2016-04-713289. Epub 2016 Sep 1. Review.


T cells from hemophilia A subjects recognize the same HLA-restricted FVIII epitope with a narrow TCR repertoire.

Ettinger RA, Paz P, James EA, Gunasekera D, Aswad F, Thompson AR, Matthews DC, Pratt KP.

Blood. 2016 Oct 20;128(16):2043-2054. doi: 10.1182/blood-2015-11-682468. Epub 2016 Jul 28.


Avidity of human T cell receptor engineered CD4(+) T cells drives T-helper differentiation fate.

Adair P, Kim YC, Pratt KP, Scott DW.

Cell Immunol. 2016 Jan;299:30-41. doi: 10.1016/j.cellimm.2015.10.003. Epub 2015 Oct 23.


Engineering less immunogenic and antigenic FVIII proteins.

Pratt KP.

Cell Immunol. 2016 Mar;301:12-7. doi: 10.1016/j.cellimm.2015.10.008. Epub 2015 Nov 2. Review.


fVIII binds platelets + fibrin: no PS!

Pratt KP.

Blood. 2015 Sep 3;126(10):1158-9. doi: 10.1182/blood-2015-07-657924. No abstract available.


Factor VIII gene variants and inhibitor risk in African American hemophilia A patients.

Gunasekera D, Ettinger RA, Nakaya Fletcher S, James EA, Liu M, Barrett JC, Withycombe J, Matthews DC, Epstein MS, Hughes RJ, Pratt KP; Personalized Approaches to Therapies for Hemophilia (PATH) Study Investigators.

Blood. 2015 Aug 13;126(7):895-904. doi: 10.1182/blood-2014-09-599365. Epub 2015 Jan 23.


Six amino acid residues in a 1200 Å2 interface mediate binding of factor VIII to an IgG4κ inhibitory antibody.

Lin JC, Ettinger RA, Schuman JT, Zhang AH, Wamiq-Adhami M, Nguyen PC, Nakaya-Fletcher SM, Puranik K, Thompson AR, Pratt KP.

PLoS One. 2015 Jan 23;10(1):e0116577. doi: 10.1371/journal.pone.0116577. eCollection 2015.


Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses.

Kim YC, Zhang AH, Su Y, Rieder SA, Rossi RJ, Ettinger RA, Pratt KP, Shevach EM, Scott DW.

Blood. 2015 Feb 12;125(7):1107-15. doi: 10.1182/blood-2014-04-566786. Epub 2014 Dec 10.


High-resolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance.

Nguyen PC, Lewis KB, Ettinger RA, Schuman JT, Lin JC, Healey JF, Meeks SL, Lollar P, Pratt KP.

Blood. 2014 Apr 24;123(17):2732-9. doi: 10.1182/blood-2013-09-527275. Epub 2014 Mar 3.


Phenotypes of allo- and autoimmune antibody responses to FVIII characterized by surface plasmon resonance.

Lewis KB, Hughes RJ, Epstein MS, Josephson NC, Kempton CL, Kessler CM, Key NS, Howard TE, Kruse-Jarres R, Lusher JM, Walsh CE, Watts RG, Ettinger RA, Pratt KP; PATH (Personalized Alternative Therapies for Haemophilia) Study Investigators.

PLoS One. 2013 May 8;8(5):e61120. doi: 10.1371/journal.pone.0061120. Print 2013.


Presenting ADAMTS13 on a TTP-associated MHC.

Pratt KP.

Blood. 2013 Apr 25;121(17):3302-3. doi: 10.1182/blood-2013-02-483412.


Progress toward inducing immunologic tolerance to factor VIII.

Scott DW, Pratt KP, Miao CH.

Blood. 2013 May 30;121(22):4449-56. doi: 10.1182/blood-2013-01-478669. Epub 2013 Mar 15. Review.


Dangerous liaisons: how the immune system deals with factor VIII.

Wroblewska A, Reipert BM, Pratt KP, Voorberg J.

J Thromb Haemost. 2013 Jan;11(1):47-55. doi: 10.1111/jth.12065. Review.


Inhibitory antibodies in hemophilia A.

Pratt KP.

Curr Opin Hematol. 2012 Sep;19(5):399-405. doi: 10.1097/MOH.0b013e328356ed37. Review.


Haemophilia management: time to get personal?

Howard TE, Yanover C, Mahlangu J, Krause A, Viel KR, Kasper CK, Pratt KP.

Haemophilia. 2011 Sep;17(5):721-8. doi: 10.1111/j.1365-2516.2011.02517.x. Epub 2011 Jun 8. Review.


T-cell responses in two unrelated hemophilia A inhibitor subjects include an epitope at the factor VIII R593C missense site.

James EA, van Haren SD, Ettinger RA, Fijnvandraat K, Liberman JA, Kwok WW, Voorberg J, Pratt KP.

J Thromb Haemost. 2011 Apr;9(4):689-99. doi: 10.1111/j.1538-7836.2011.04202.x.


HLA-DR-restricted T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P.

Ettinger RA, James EA, Kwok WW, Thompson AR, Pratt KP.

Haemophilia. 2010 May;16(102):44-55. doi: 10.1111/j.1365-2516.2008.01905.x.


Lineages of human T-cell clones, including T helper 17/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses.

Ettinger RA, James EA, Kwok WW, Thompson AR, Pratt KP.

Blood. 2009 Aug 13;114(7):1423-8. doi: 10.1182/blood-2009-01-200725. Epub 2009 Jun 23.


Factor VIII mutations in 42 Moldovan haemophilia A families, including 12 that are novel.

Sirocova N, Tsourea V, Vicol M, Barbacar N, Nakaya SM, Thompson AR, Pratt KP.

Haemophilia. 2009 Jul;15(4):942-51. doi: 10.1111/j.1365-2516.2009.02021.x. Epub 2009 Apr 20.


B-cell and T-cell epitopes in anti-factor VIII immune responses.

Pratt KP, Thompson AR.

Clin Rev Allergy Immunol. 2009 Oct;37(2):80-95. doi: 10.1007/s12016-009-8120-7. Review.


Covalent inactivation of factor VIII antibodies from hemophilia A patients by an electrophilic FVIII Analog.

Planque S, Escobar MA, Smith KC, Taguchi H, Nishiyama Y, Donnachie E, Pratt KP, Paul S.

J Biol Chem. 2008 May 2;283(18):11876-86. doi: 10.1074/jbc.M800589200. Epub 2008 Mar 11.


The factor VIII C1 domain contributes to platelet binding.

Hsu TC, Pratt KP, Thompson AR.

Blood. 2008 Jan 1;111(1):200-8. Epub 2007 Oct 4.


ELISA system for detection of immune responses to FVIII: a study of 246 samples and correlation with the Bethesda assay.

Sahud MA, Pratt KP, Zhukov O, Qu K, Thompson AR.

Haemophilia. 2007 May;13(3):317-22.


Induction of partial immune tolerance to factor VIII through prior mucosal exposure to the factor VIII C2 domain.

Rawle FE, Pratt KP, Labelle A, Weiner HL, Hough C, Lillicrap D.

J Thromb Haemost. 2006 Oct;4(10):2172-9. Epub 2006 Jul 5.


Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site.

Pratt KP, Qian J, Ellaban E, Okita DK, Diethelm-Okita BM, Conti-Fine B, Scott DW.

Thromb Haemost. 2004 Sep;92(3):522-8.


New insights into binding interfaces of coagulation factors V and VIII and their homologues lessons from high resolution crystal structures.

Fuentes-Prior P, Fujikawa K, Pratt KP.

Curr Protein Pept Sci. 2002 Jun;3(3):313-39. Review.


Relating structure to function: the role of the C2 domain in Factor VIII.

Pratt KP.

Curr Opin Drug Discov Devel. 2000 Sep;3(5):516-26.


Hemophilic factor VIII C1- and C2-domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure.

Liu ML, Shen BW, Nakaya S, Pratt KP, Fujikawa K, Davie EW, Stoddard BL, Thompson AR.

Blood. 2000 Aug 1;96(3):979-87.


Structure of the C2 domain of human factor VIII at 1.5 A resolution.

Pratt KP, Shen BW, Takeshima K, Davie EW, Fujikawa K, Stoddard BL.

Nature. 1999 Nov 25;402(6760):439-42.


Crystal structure of a 30 kDa C-terminal fragment from the gamma chain of human fibrinogen.

Yee VC, Pratt KP, Côté HC, Trong IL, Chung DW, Davie EW, Stenkamp RE, Teller DC.

Structure. 1997 Jan 15;5(1):125-38.

Supplemental Content

Loading ...
Support Center